In the year 2020, patients who received a heart transplant had a 90 percent chance of surviving the first year after transplantation. The statistic shows the percentage of organ transplant patients who survived one, three, and five-years after transplantation in the U.S. in 2020, by organ type.

The only national patient waiting list and an online database system, called UNet, that links all of the professionals involved in the donation and transplantation system for the collection, storage, analysis, and publication of all OPTN data pertaining to the patient waiting list, organ matching, and transplants. The system contains data regarding every organ donation and transplant event occurring in the U.S. since October 1, 1987. UNet is a fail-safe, 24/7, secure Internet-based transplant information database created to enable the nation''''s organ transplant institutions to: * register patients for transplants * match donated organs to waiting patients * manage the time-sensitive, life-critical data of all patients, before and after their transplants Data reports are available by type: National Data, Regional Data, State Data, Center Data, Build Advanced Report, and Annual Report Data. UNet is being used right now by all of the nation''''s organ transplant programs, organ procurement organizations, and histocompatibility (tissue typing) laboratories working cooperatively to efficiently share a limited number of donated organs among thousands of patients.

Organ Transplantation Market Outlook

The global organ transplantation market size was valued at approximately USD 10.5 billion in 2023 and is projected to reach USD 18.7 billion by 2032, growing at a CAGR of 6.7% during the forecast period. This significant growth is driven by advancements in medical technology, increasing prevalence of chronic diseases, and improved post-transplant outcomes. Notably, the growing demand for organ transplants is paralleled by an increase in organ donation awareness and governmental initiatives aimed at promoting organ donation and transplantation.

The primary growth factor for the organ transplantation market is the rising incidence of chronic diseases, such as diabetes, hypertension, and heart disease, which often lead to organ failure. Organ transplantation is increasingly seen as a viable treatment option for end-stage organ failure, leading to higher demand for transplantation procedures. Additionally, medical advancements, such as improved surgical techniques and better immunosuppressive drugs, have significantly increased the success rates of organ transplants, thus bolstering market growth.

Another major growth driver is the increasing awareness and initiatives around organ donation. Governments and non-government organizations worldwide are actively promoting organ donation through various campaigns and educational programs. These efforts aim to alleviate the chronic shortage of donor organs by encouraging more people to register as donors. The implementation of policies and laws facilitating organ donation and procurement processes has also played a crucial role in increasing the availability of donor organs, thereby positively impacting the market.

Technological advancements in organ preservation and transplantation techniques are also contributing to the market growth. Innovations such as hypothermic machine perfusion for organ preservation and the development of bioengineered organs have opened new possibilities in organ transplantation. These advancements not only improve the viability and success rates of transplanted organs but also extend the preservation time, allowing for better matching and planning of transplantation procedures. Consequently, these technological breakthroughs are expected to fuel the growth of the organ transplantation market in the coming years.

The role of Transplantation Diagnostics has become increasingly vital in the organ transplantation market. These diagnostics are crucial for assessing donor-recipient compatibility, which is a key factor in the success of transplantation procedures. Advanced diagnostic tools, such as molecular assays and genetic testing, enable precise matching and reduce the risk of organ rejection. As the demand for organ transplants continues to rise, the need for accurate and efficient transplantation diagnostics is more important than ever. These diagnostics not only help in pre-transplant evaluations but also play a significant role in post-transplant monitoring, ensuring the long-term health and functionality of the transplanted organ. The integration of innovative diagnostic technologies is expected to enhance transplantation outcomes and drive growth in this segment.

Regionally, North America holds the largest share in the organ transplantation market, primarily due to the high prevalence of chronic diseases, advanced healthcare infrastructure, and supportive government policies. However, Asia Pacific is expected to witness the highest growth rate during the forecast period, driven by increasing healthcare expenditure, growing awareness about organ donation, and improving healthcare facilities. The rising number of organ transplant procedures and the establishment of transplant centers in emerging economies like India and China are anticipated to further propel the market growth in this region.

Organ Type Analysis

The kidney segment dominates the organ transplantation market due to the high incidence of chronic kidney disease and end-stage renal disease worldwide. Kidney transplantation is considered the most effective treatment for patients with severe kidney failure, providing better quality of life and survival rates compared to dialysis. The increasing prevalence of diabetes and hypertension, which are major risk factors for kidney disease, further drives the demand for kidney transplants. Additionally, advancements in surgical techniques and immunosuppressive therapies have significantly improved the success rates of kidney

In 2023, there were 46,629 organ transplants in the United States. This was the highest number ever, with the second-highest number of transplants reported in 2022. In the United States, the most commonly transplanted organs are the kidneys, liver, and heart. Who donates organs in the United States? In 2023, there were almost 23,300 organ donors in the United States. Men accounted for around 55 percent of organ donors that year. Some organs, such as a kidney, can be donated while the donor is alive, but most donations occur after the donor has deceased. For this reason, it is no surprise that most organ donors in the United States are older adults. In 2022, the highest number of organ donors were in the age group 50-64 years. Although the number of organ donors in the U.S. has increased gradually over the past few decades, those requiring an organ transplantation still far outnumber donors, with thousands currently on waiting lists to receive an organ transplantation that may save their life. Waiting lists for transplants In the United States, there were 104,753 candidates waiting for an organ transplantation as of December 2024. Around 86 percent of these candidates were waiting for a kidney transplantation, while nine percent needed a liver transplant. Older adults are more likely to need an organ transplant than younger people, with those aged 50 to 64 years accounting for the highest number of candidates on organ donation waiting lists. The organ with the longest average waiting time in the United States is the kidney. As of 2017, a candidate in the U.S. that required a kidney transplant could expect to wait around 685 days. In comparison, those requiring a heart transplant could expect a wait of 213 days.

As demand for a healthy liver rises, the current market value for liver transplants is likely to reach US$ 1,409.8 million. The market is expected to be worth around US$ 2,653.4 million by 2033. The market for liver transplants is estimated to record a growth of 6.5% during the forecast period.

Attributes	Key Statistics
Expected Base Year Value (2023)	US$ 1,409.8 million
Anticipated Forecast Value (2033)	US$ 2,653.4 million
Estimated Growth (2023 to 2033)	6.5% CAGR

Historical Outlook of the Liver Transplantation Market Compared to the Forecast Period

Attributes	Details
Market Size (2022)	US$ 1,340.3 million
CAGR (2017 to 2022)	4.2%

Region-wise Outlook

Attributes	Details
North America Market Share (2022)	29.2%
Europe Market Share (2022)	20.7%

Country-wise Analysis

Country	The United States
Value Share in 2022	25.8%

Country	Germany
Value Share in 2022	5.3%

Country	Japan
Value Share in 2022	5.2%

Country	China
Value Share in 2022	7.7%

Country	India
Value Share in 2022	6.3%

Category-wise Insights

Top Segment	Liver Transplantation Surgery
Market Share	61.1%

Top Segment	Hospitals
Market Share	51.2%

The Report Covers Global Organ Transplantation Market Statistics & Size and the Market is Segmented by Product (Tissue Products, Immunosuppressive Drugs, Preservation Solution), Application (Organ Transplantation, Tissue Transplantation), End-Use (Hospitals, Transplant Centers, Others), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market provides the value (in USD million) for the above segments.

In 2023, there were 809 organ transplants for individuals between the ages of 11 and 17 years old. Organ donation can be given through both a deceased and living donor if blood and oxygen are flowing through the organs until the time of recovery to ensure viability. There are over 100,000 people in the country waiting for an organ transplant. This statistic displays the number of organ transplants performed in the United States, by age group, in 2023.

The Organ Transplantation Market Report is Segmented by Organ Type (Kidney, Liver, Heart, Pancreas, and Other Organ Types), Type of Transplant (Allogenic, Autologous, and Other Types of Transplants), Product Type (Organ Preservation Products, Transplant Diagnostics, Immunosuppressants Drugs, Tissue Products, and Other Product Types), End User (Hospitals, Transplant Centers, and Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Report Offers Market Sizes and Forecasts for all the Above Segments in Value (USD).

Tissue and Organ Transplantation Market size is expected to reach USD 44 Bn by 2033 from USD 17.7 Bn in 2023, at a CAGR of 9.5% (2024-2033).

Introduction

The Tissue and Organ Transplantation market is projected to reach approximately USD 44 billion by 2033, growing from USD 17.7 billion in 2023. This represents a compound annual growth rate (CAGR) of 9.5% from 2024 to 2033. Key growth drivers include technological advancements in transplant technologies and surgical techniques, which enhance organ transplant success rates and extend the lifespan of transplanted organs.

Legislative support and policy reforms are crucial for expanding the donor pool and reducing wait times by streamlining organ donation processes. Efforts include facilitating the safe transport of organs and accommodating organs from non-traditional donors, such as older individuals. Additionally, increasing public awareness through campaigns and educational programs significantly boosts organ donor registration rates, directly impacting the number of organs available for transplantation.

Improvements in the transplant system are also vital. The Organ Procurement and Transplantation Network (OPTN) and related entities focus on enhancing organ allocation equity, improving transparency, and supporting advancements in donor management and organ matching. Collaborative efforts between hospitals, organ procurement organizations, and transplant centers optimize the donation process, ensuring organs are preserved and transported effectively to recipients in optimal condition.

These combined efforts contribute to the robust growth and resilience of the tissue and organ transplantation sector, ultimately aiming to save more lives through improved and accessible transplantation services.

https://market.us/wp-content/uploads/2022/07/Tissue-and-Organ-Transplantation-Market-Growth.jpg" alt="Tissue and Organ Transplantation Market Growth">

The global hematopoietic stem cell transplantation market garnered a market value of US$ 7 Billion in 2023 and is expected to accumulate a market value of US$ 15 Billion by registering a CAGR of 8% in the forecast period 2023 to 2033. Because of the rising frequency of leukemia and lymphoma, the worldwide hematopoietic stem cell transplantation industry is predicted to rise significantly over the forecast period.

Data Points	Key Statistics
Expected Market Value (2023)	US$ 7 Billion
Anticipated Forecast Value (2033)	US$ 15 Billion
Projected Growth Rate (2023 to 2033)	8% CAGR

Report Scope

Report Attribute	Details
Market Value in 2023	US$ 7 Billion
Market Value in 2033	US$ 15 Billion
Growth Rate	CAGR of 8% from 2023 to 2032
Base Year for Estimation	2021
Historical Data	2018 to 2022
Forecast Period	2023 to 2033
Quantitative Units	Revenue in US Billion and CAGR from 2023 to 2032
Report Coverage	Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered	Transplant Type Indication Application Region
Regions Covered	North America Latin America Europe Asia Pacific Middle East & Africa (MEA)
Key Countries Profiled	USA Canada Brazil Mexico Germany UK France Spain Italy China Japan South Korea India Malaysia Singapore Australia New Zealand GCC South Africa Israel
Key Companies Profiled	Pluristem Therapeutics Inc. CellGenix GmbH Regen Biopharma Inc. Lonza Group Sanofi Taiga Biotechnologies, Inc. Takeda Pharmaceutical Company Limited Escape Therapeutics, Inc. Bluebird Bio Talaris Therapeutics
Customization	Available Upon Request

Collect, analyze, and communicate on comprehensive and current data on all islet/beta cell transplants in human recipients performed in North America, as well as some European and Australian centers to expedite progress and promote safety in islet/beta cell transplantation. This site serves as a repository for general information concerning protocols, clinical transplantation sites, publications, and other information of interest to the general community. Annual Reports are available. Islet/beta cell transplantation is a complex procedure with many factors contributing to the outcome. Compiling and analyzing data from all transplant centers in the US, Canada, as well as some European and Australian centers will accelerate the identification of both critical risk factors and key determinants of success and thereby guide transplant centers in developing and refining islet/beta cell transplant protocols. The inclusion of the term collaborative in the name of the Registry emphasizes the importance of collaboration in fulfilling the CITR mission and goals. Close collaboration with the transplant centers will ensure that relevant questions are addressed, that data submitted are accurate and complete, and that the needs of the transplant community are served. Information on how to participate as a CITR Transplant Center and to receive a transplant center application is available through the website. Progress in islet transplantation depends entirely on complete, high-quality medical data, including the information patients consented to report to the Collaborative Islet Transplant Registry. To make it as easy as possible to provide updated information about patient's health, an on-line questionnaire is available or patients can mail it to their transplant center. This information is very important in the continuing search for a cure for Type 1 diabetes.

Organ and Tissue Transplantation and Alternatives Market Outlook

The global organ and tissue transplantation and alternatives market is poised to achieve remarkable growth, projected to reach USD 50 billion by 2032, driven by advancements in medical technology and an increasing prevalence of organ failure conditions. This market is characterized by a complex interplay of growth factors, including technological innovations, rising awareness about organ donation, and a growing geriatric population.

One of the primary growth factors for this market is technological innovation. Advances in surgical techniques, post-transplant care, and the development of bioartificial organs have significantly improved transplantation outcomes. For instance, the advent of 3D bioprinting technology has the potential to revolutionize the field by creating bioartificial organs that can be customized for individual patients, reducing the risk of organ rejection and the need for immunosuppressive drugs. Moreover, regenerative medicine, which aims to repair or replace damaged tissues and organs, is making significant strides, further pushing the boundaries of transplantation possibilities.

Increasing awareness about organ donation is another crucial driver. Governments and non-profit organizations worldwide are actively campaigning to encourage organ donation, resulting in a gradual increase in the number of registered donors. Programs like 'Donate Life America' and various organ donation awareness weeks have played a pivotal role in educating the public about the importance of organ donation. Additionally, advancements in matching donor organs with recipients have improved transplant success rates, making the process more efficient and reliable, thereby boosting the market.

The growing geriatric population also contributes significantly to market growth. As the global population ages, there is an increased incidence of organ failure conditions such as end-stage renal disease, liver cirrhosis, and heart failure. Older adults are more susceptible to chronic diseases that often lead to the need for organ transplants. This demographic shift is increasing the demand for both organ and tissue transplantation procedures, driving market expansion.

The use of Organ Transplant Immunosuppreant is a cornerstone in the management of patients undergoing organ transplantation. These drugs are essential to prevent the body's immune system from rejecting the transplanted organ. The development of new immunosuppressive agents has been pivotal in improving the success rates of organ transplants. By minimizing the risk of rejection, these medications have enabled longer graft survival and better quality of life for transplant recipients. Continuous research is focused on optimizing these therapies to reduce side effects and enhance patient outcomes, making them a critical component of the transplantation process.

Regionally, North America holds the largest share of the organ and tissue transplantation market, mainly due to well-established healthcare infrastructure, high healthcare expenditure, and favorable reimbursement policies. However, the Asia Pacific region is expected to witness the fastest growth during the forecast period. Factors such as improving healthcare facilities, increasing awareness about organ donation, and supportive government initiatives are propelling market growth in this region. Countries like India, China, and Japan are emerging as significant contributors to the market, with increasing numbers of transplant centers and advanced medical technologies.

Type Analysis

The organ transplantation segment is a critical component of the market, encompassing a wide range of procedures, including kidney, liver, heart, lung, and pancreas transplants. Kidney transplantation remains the most commonly performed procedure due to the high prevalence of chronic kidney disease and end-stage renal disease. Advances in immunosuppressive therapy have significantly improved the success rates of kidney transplants, making it a viable long-term solution for patients. The liver transplantation segment is also growing, driven by the increasing incidence of liver cirrhosis and hepatocellular carcinoma. The development of living-donor liver transplantation techniques has mitigated the shortage of deceased donor organs, enhancing the segment's growth.

Tissue transplantation includes bone marrow, cornea, skin, and v

The global organ transplantation market was valued at USD 6.81 Million in 2025 and is projected to grow at a CAGR of 8.93% over the forecast period (2025-2033). The growth of the market can be attributed to the increasing prevalence of chronic diseases, rising demand for organ transplantation procedures, and advancements in organ preservation and transplantation techniques. The key drivers include the increasing incidence of end-stage organ failure due to factors such as diabetes, cardiovascular diseases, and liver cirrhosis, as well as the growing awareness about organ donation and transplantation. The market is segmented by organ type, type of transplant, product type, and end user. The largest segment by organ type is the kidney transplant segment, which accounted for over 50% of the market share in 2025. The allogenic transplant segment is the largest by type of transplant, followed by the autologous transplant segment. The immunosuppressant drugs segment is the largest by product type due to the high usage of these drugs to prevent organ rejection. Hospitals are the largest end user, accounting for over 60% of the market share in 2025. The key market players include Novartis AG, AbbVie Inc., Sanofi SA, Medtronic PLC, Organ Recovery Systems Inc., TransMedics Inc., Veloxis Pharmaceuticals, Paragonix Technologies Inc., F Hoffmann-La Roche Ltd., Arthrex Inc., and BioLife Solutions. Recent developments include: August 2024: Getinge signed an agreement to acquire 100% of Paragonix Technologies Inc., a premier US-based company specializing in organ transport products and services, for USD 477 million. By acquiring Paragonix Technologies, Getinge stepped into a rapidly evolving domain spurred by increasing transplant volumes, technological advancements, and changing clinical practices. The acquisition aligned with Getinge's overarching strategy to broaden its portfolio in high-growth markets. These markets not only complement but also bolster Getinge's existing acute heart and lung support offerings.July 2024: The State Government of Kerala, India, established an Institute of Organ and Tissue Transplant as an Apex Institute for research, training, and patient care in the area of organ transplantation and allied activities at Kozhikode.. Key drivers for this market are: Increasing Number of Organ Transplants Due to Chronic Diseases, Technological Advancements in Tissue Engineering and Organ Transplantations; Rising Awareness and Government Initiatives for Organ Donation and Transplantation. Potential restraints include: Increasing Number of Organ Transplants Due to Chronic Diseases, Technological Advancements in Tissue Engineering and Organ Transplantations; Rising Awareness and Government Initiatives for Organ Donation and Transplantation. Notable trends are: Immunosuppressant Drugs Segment Expected to Witness Significant Growth Over the Forecast Period.

The Organ Preservation Solutions segment is projected to witness substantial growth due to the increasing demand for extended organ viability during transportation and storage. Transplant Diagnostics plays a vital role in assessing organ function and compatibility, driving market growth. Tissue Products, such as bioengineered scaffolds and regenerative medicine approaches, are gaining attention for their potential to improve transplant outcomes and reduce the need for donor organs. Recent developments include: March 2022:Immucor, Inc., a business specializing in transfusion and transplantation diagnostics, recently announced the addition of two new products to its portfolio of transplant diagnostics, proving its continued dedication to recent developments in the histocompatibility sector., March 2022:To focus on the commercialization of HepatoPredict, a predictive gene expression signature test to determine which patients may benefit from liver transplantation, Biocartis, and Ophiomics collaborated.. Notable trends are: Growing donation of organs to boost market growth.

A kidney transplant was the most carried out transplant in the European Union in 2023, with over 18.2 thousand procedures carried out across the continent. Furthermore, around 7.6 thousand liver transplants and 2.2 thousand heart transplants were also carried out.

The U.S. Transplantation Market size was valued at USD 11.37 Billion in 2023 and is projected to reach USD 12.43 Billion by 2032, exhibiting a CAGR of 9.1 % during the forecast period. Transplantation is the medical process of moving an organ to another person to replace a critically damaged part of the body. The other features of transplantation are that the organ must be cross-matched for acceptance by the recipient’s immune system and the necessity of administering immunosuppressive drugs to prevent rejection. There are also many benefits to being a transplant recipient. It can save lives, especially where organ failures take place, like in the kidneys, heart, or liver. For instance, kidney transplants often enable patients to avoid dialysis, and the consequences of the procedure on their quality of life are significant. Heart and liver transplant recipients will thus have their lives prolonged as well as their general body condition improved. The ability to function daily is also restored in cases such as corneal transplants for the improvement of sight or bone marrow transplants for the treatment of cancer or blood diseases. Recent developments include: January 2023 – Zimmer Biomet Holdings, Inc. underwent a definitive agreement to acquire Embody, Inc. This acquisition includes Embody's complete portfolio of collagen-based biointegrative solutions, including the TAPESTRY, a biointegrative implant for tendon healing, and TAPESTRY RC, one of the first arthroscopic implant systems for rotator cuff repair., July 2021 – TransMedics Group, Inc. received 510(k) clearance from the regulatory body U.S. Food and Drug Administration for OCS Lung Solution for use in transplants using cold storage techniques., December 2020 – Biocon launched Tacrolimus capsules in the U.S. It is a calcineurin inhibitor used in organ transplant patients and helps to reduce the body’s ability to reject a transplanted organ.. Key drivers for this market are: Strong Demand for these Procedures to Augment Market Growth. Potential restraints include: Growing Competition from Generic Immunosuppressants to Hinder Market Growth. Notable trends are: Strategic Initiatives among Various Organizations to Augment These Procedures is a Positive Market Trend.

The global Organ Transplantation Market size is expected to reach USD 33.65 Billion in 2032 registering a CAGR of 8.3%. Our report provides a comprehensive overview of the industry, including key players, market share, growth opportunities and more.

This statistic depicts rates of selected organ transplantations in the United States in 2008 and 2023, per million inhabitants. In 2008, the rate of lung transplants per million inhabitants in the United States was 4.9. By 2023, this rate increased to 9.1.